CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued

Article Stock Quotes (1) Comments (0)

CRT Capital's Timothy Chiang downgraded shares of Valeant Pharmaceuticals (NYSE: VRX) from Buy to Fairly Valued Thursday afternoon.

The downgrade follows Q1 results from the company and news it will acquire AcneFree and certain assets from University Medical. Shares are down more than 9 percent at last check.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Valeant Pharmaceuticals Prices Public Offering Of Common Shares
• Baird Downgrades Sonoco Products (SON) to Neutral
• StreetInsider.com Pre-Open Movers 6/18: (WLT) (SNE) (RMBS) Higher; (SFL) (HRL) (GNMK) Lower (more...)

Create E-mail Alert Related Categories

Downgrades

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?